The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID).This was a 3-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, wash-out study conducted in 57 amantadine-treated (≥200 mg/d for ≥6 months) dyskinetic patients with PD. The primary outcome measure was the change from baseline in a Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia subscore (items 32 [duration] + 33 [severity]). Secondary outcomes included other LID measurements ("responders" analysis, premature dropout for LID, Abnormal Involuntary Movement Scale). Exploratory outcomes included time with troublesome dyskinesia as measured by diaries, UPDRS Motor Examination (part III) for motor symptoms of PD, and fatigue and apathy scores for nonmotor symptoms.UPDRS items 32 + 33 deteriorated more in patients switched to placebo ("discontinuing" group) (+1.7 ± 2.0 units; 95

作者：Fabienne, Ory-Magne；Jean-Christophe, Corvol；Jean-Philippe, Azulay；Anne-Marie, Bonnet；Christine, Brefel-Courbon；Philippe, Damier；Estelle, Dellapina；Alain, Destée；Franck, Durif；Monique, Galitzky；Thibaud, Lebouvier；Wassilios, Meissner；Claire, Thalamas；Fran?ois, Tison；Alexandrine, Salis；Agnès, Sommet；Fran?ois, Viallet；Marie, Vidailhet；Olivier, Rascol

来源：Neurology 2014 年 82卷 4期